Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MDM4 | O15151 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 2/20 | 0.45 |
| ▸ | FDFT1 | P37268 | 2/20 | 0.44 |
| ▸ | NMBR | P28336 | 1/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5963320 | 1.00 | KMT2A (0.48) | KMT2AMDM4TP53CASP3FDFT1 | |
| SCHEMBL5963770 | 0.93 | KMT2A (0.47) | KMT2AMDM4TP53CASP3FDFT1 | |
| SCHEMBL2245010 | 0.88 | KMT2A (0.54) | KMT2AMDM4TP53CASP3 | |
| SCHEMBL14787476 | 0.86 | KMT2A (0.51) | KMT2AMDM4TP53CASP3FDFT1 | |
| SCHEMBL30554761 | 0.86 | KMT2A (0.51) | KMT2AMDM4TP53CASP3FDFT1 | |
| SCHEMBL17446719 | 0.85 | PTPN1 (0.48) | KMT2AMDM4TP53 | |
| SCHEMBL14787175 | 0.84 | MDM4 (0.48) | KMT2AMDM4TP53CASP3FDFT1 | |
| SCHEMBL26980990 | 0.84 | TLR2 (0.54) | KMT2A | |
| SCHEMBL26980963 | 0.84 | TLR2 (0.54) | KMT2A | |
| SCHEMBL14787531 | 0.83 | MDM4 (0.52) | MDM4TP53CASP3FDFT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11866518-B2 | Bicyclic peptide ligands specific for TSLP | BICYCLETX LIMITED (GB) | 2024-01-09 | — | — | US | disclosed |
| EP-4132481-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TSLP | BicycleTX Limited (GB) | 2023-02-15 | — | — | EP | disclosed |
| US-20220363718-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TSLP | BICYCLETX LIMITED (GB) | 2022-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220363718-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TSLP | TSLP, VIP, CCL2 | KMT2A 4455/4885MDM4 2209/4885TP53 300/4885 |
| US-11866518-B2 | Bicyclic peptide ligands specific for TSLP | TSLP, VIP, CCL2 | KMT2A 4455/4885MDM4 2209/4885TP53 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.